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Abstract
OBJECTIVE—Certain D2 dopamine receptor Taq 1A genotypes (A1A1, A1A2) have been
associated with obesity and substance abuse. We hypothesized that their presence would be
associated with reduced efficacy of dietary interventions in individuals with type 2 diabetes.
RESEARCH METHODS & PROCEDURES—In the course of a randomized clinical trial in an
outpatient research center in which 93 adults with type 2 diabetes were assigned to a low-fat vegan
diet or a diet following 2003 American Diabetes Association guidelines for 74 weeks, Taq 1A
genotype was determined. Nutrient intake, body weight, and hemoglobin A1c (A1c) were measured
over 74 weeks.
RESULTS—The A1 allele was highly prevalent, occurring in 47% of white participants (n = 49),
which was significantly higher than the 29% prevalence previously reported in nondiabetic whites
(P=0.01). The A1 allele was found in 55% of black participants (n = 44). Black participants with A1
+ genotypes had significantly greater mean body weight (11.2 kg heavier, P=0.05), and greater intake
of fat (P=0.002), saturated fat (P=0.01) and cholesterol (P=0.02), compared with A2A2 (A1-)
individuals; dietary changes during the study did not favor one genotype group. Among whites,
baseline anthropometric and nutrient differences between gene groups were small. However, among
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whites in the vegan group, A1+ individuals reduced fat intake (P=0.04) and A1c (P=0.01)
significantly less than did A1- individuals.
CONCLUSIONS—The A1 allele appears to be highly prevalent among individuals with type 2
diabetes. Potential influences on diet, weight, and glycemic control merit further exploration.
Keywords
dopamine; DRD2; diabetes; vegetarian diet
INTRODUCTION
The A1 allele of the Taq1A polymorphism (rs1800497), located ≈10 kb downstream of the D2
dopamine receptor (DRD2) gene (1), has been investigated for possible associations with
habitual use of alcohol (2,3), cocaine (4), nicotine (5-8), and opioids (9). Evidence indicates
that individuals carrying this allele have reduced brain D2 receptor density, compared with
other individuals (10-13). It has been suggested that persistent substance abuse in individuals
with the A1 allele may be a form of self-stimulatory behavior that compensates for insufficient
dopamine activity (14).
The A1 allele is also associated with obesity (15-17). Food consumption, like use of alcohol
and drugs of abuse, increases dopamine concentrations in the nucleus accumbens (18),
activating the mesocortiolimbic dopaminergic reward pathways of the brain (19), resulting in
the reinforcing effects of euphoria or pleasure.
Among the sequelae of obesity is type 2 diabetes, and altering dietary habits is an important
focus of diabetes treatment. Surprisingly, no data are available on the prevalence of the A1
allele or its possible influences on dietary behavior among individuals with type 2 diabetes.
We therefore sought to assess the prevalence of the A1 allele among individuals with diabetes
and to explore whether individuals with the A1 allele would show differences in dietary habits
or be less likely to adhere to therapeutic diets, compared with other individuals. In the course
of a dietary trial among individuals with type 2 diabetes, we investigated the distribution of
DRD2 genotypes and examined their associations with dietary intake and clinical outcomes.
MATERIALS AND METHODS
Participants
The methods for the overall study have been previously described (20). Briefly, individuals
with type 2 diabetes mellitus, defined by a fasting plasma glucose concentration ≥126 mg/dl
on 2 occasions or a prior physician’s diagnosis of type 2 diabetes with the use of hypoglycemic
medications for at least 6 months, were recruited through newspaper advertisements in the
Washington, D.C., area. Exclusionary criteria included hemoglobin A1c (A1c) values <6.5%
or >10.5%, use of insulin for >5 years, tobacco use within the preceding 6 months, alcohol or
drug abuse, pregnancy, unstable medical status, and current use of a low-fat, vegetarian diet.
Definition of race/ethnicity was required by the National Institutes of Health to ascertain
balance in group assignments and assess the degree to which the participant sample reflected
the community from which it was drawn. Participants were asked to describe themselves as
white; black; American Indian, Eskimo, Aleut; or Asian, Pacific Islander; and describe their
ethnicity as either Hispanic or non-Hispanic. The protocol was approved by the George
Washington University Institutional Review Board. All participants gave written informed
consent.
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After medical history and physical examination, blood samples were drawn and A1c was
assayed using affinity chromatography on an Abbott IMx analyzer (21). Volunteers were then
ranked in order of A1c concentrations. Using a computer-generated random-number table, we
randomly assigned participants in sequential pairs to a low-fat, vegan diet or a diet following
2003 ADA guidelines (22). Genomic DNA was extracted from participants’ blood samples
using standard methods. The PCR method for determining DRD2 Taq IA genotypes has been
previously described (23). Two alleles were found: A1 [310 b.p.] and A2 [180 b.p. and 130
b.p.] alleles. Participants were considered A1+ if they carried the A1A1 or A1A2 genotype.
Participants were considered A1- if they carried the A2A2 genotype. Genotype was not
considered in the randomization process.
Intervention
The vegan diet (approximately 10% of energy from fat, 15% protein, 75% carbohydrate)
consisted of vegetables, fruits, grains, and legumes. Animal products were proscribed, and
added oils, avocados, olives, nuts, nut butters, and seeds were discouraged to reduce the fat
and energy content of the diet. Vegan-group participants were also asked to favor low-
glycemic-index foods (24), such as beans and green leafy vegetables. Portion sizes, energy
intake, and carbohydrate intake were not limited.
For ADA group participants, dietary energy, carbohydrate, and monounsaturated fat content
were individualized, based on each participant’s need to reduce body weight and plasma lipid
concentrations, following ADA guidelines (22). The diet derived 15-20% of energy from
protein and <7% of energy from saturated fats. Carbohydrate and monounsaturated fats
together provided 60-70% of energy intake. Dietary cholesterol was limited to 200 mg/day.
ADA-group participants with a body mass index >25 kg/m2 were prescribed energy intake
limits set at 500-1000 kcal below those estimated as required for weight maintenance. Because
the purpose of the overall study was to compare the two diets’ effects on glycemia, weight,
and lipid control, recognizing that the diets may achieve these ends by different mechanisms,
the two diets were not designed to be isocaloric.
All participants were provided a vitamin B12 supplement (100 mcg, to be taken every other
day). For both groups, alcoholic beverages were limited to 1 drink per day for women, and 2
drinks per day for men.
No meals were provided. Participants were asked not to alter their exercise habits during the
initial 22 weeks of the intervention period.
Each participant met with a registered dietitian for 1 hour to establish a diet plan consistent
with the assigned diet guidelines. Thereafter, participants attended weekly 1-hour meetings of
their assigned groups for nutrition and cooking instruction and group discussions for 22 weeks.
For the following 52 weeks, these sessions were biweekly. A 3-day dietary record was
completed by each participant at weeks 0, 11, 22, and 74 on 2 weekdays and 1 weekend day,
using a food scale, after participants had completed a practice record for 3 days. Using the
Nutrition Data System for Research software version 5.0, developed by the Nutrition
Coordinating Center, University of Minnesota, Minneapolis, MN, Food and Nutrient Database
35 (25), released May 2004, a registered dietitian certified by the Nutrition Coordinating Center
analyzed all 3-day dietary records and diet recalls.
Participants were asked to maintain their use of medications as prescribed by their personal
physicians prior to the study, except when fasting plasma glucose fell below 4.4 mmol/L (80
mg/dl) or hypoglycemic symptoms were accompanied by a capillary glucose reading <3.6
mmol/L.(65 mg/dl). In such cases, medications were reduced for participant safety by a study
endocrinologist, who remained blind to group assignment, following an established protocol.
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Body weight was determined at weeks 0, 22, and 74, before breakfast while participants wore
hospital gowns, using a digital scale accurate to 0.1 kg. Waist circumference was measured
with a tape measure placed 2.5 cm above the umbilicus. Hip circumference was measured at
the maximal protrusion of the buttocks. Values were rounded to the nearest 0.5 cm.
A1c was measured with method described above at weeks 0, 11, 22, 35, 48, 61, and 74, after
a 12-hour fast, by technicians blind to group assignment.
Statistical Analyses
Data analyses for the current report were limited to black or white participants, due to small
numbers of individuals of other races, and data were analyzed separately for black and white
participants. We compared the prevalence of the A1+ genotypes among white participants in
the present sample to that previously found among demographically comparable groups of
nondiabetic white individuals (26), using a Chi-Square test for proportions. Similar previous
comparative data were not available for black participants.
Between-subjects t-tests were calculated for each measure to determine whether baseline
characteristics among participants with the A1- genotype differed from those of participants
with the A1+ genotypes. The relationship of the A1 genotypes with weight or BMI was assessed
using linear regression analysis, controlled for age and sex.
Exploratory analyses were conducted for associations between genotype and dietary or clinical
changes during the study, but were interpreted cautiously, due to small numbers in some cells.
Paired comparison t-tests were calculated to test whether the change from baseline to 74 weeks
was significantly different from zero. To assess differences between A1+ and A1- genotype
groups in the changes from baseline to 74 weeks, we conducted multiple regression models to
examine the effects of race (black or white), diet group (vegan or ADA), and genotype (A1+
or A1-) on nutrient intake changes and on clinical measure changes (SAS PROC GLM). Based
on these regressions, we conducted additional t-test comparisons of A1- and A1+ participants
within racial and diet groups.
The primary analysis of the main end-point included all participants. Because medication
changes influence the dependent measures, A1c changes were also analyzed for changes from
baseline to the last value before any alteration in hypoglycemic medications. An alpha of 0.05
was used for all statistical tests, with no adjustment for multiple comparisons.
RESULTS
Of 1,049 individuals initially screened by telephone, 99 met study criteria and were randomly
assigned to the vegan (n = 49) and ADA (n = 50) diet groups. Reasons for exclusion were: A1c
values outside the required range (n = 201), failure to meet other participation criteria (n =
279), inability to attend scheduled meetings (n = 187), failure to keep interview appointment
(n = 153), reluctance to change diet (n = 72), and other or unspecified (n = 58). Limiting the
present study to black or white individuals, the population included 44 black and 49 white
participants. The sample was predominantly female, married, and well-educated (Table I).
There were no significant demographic differences between A1- and A1+ participants.
Six A1- and 6 A1+ participants failed to complete laboratory assessments at 74 weeks and 9
A1- participants and 7 A1+ participants failed to complete 74-week dietary records. There were
no significant differences between these individuals and study completers. During the 74-week
study period, 39% (18/46) of A1- participants and 49% (23/47) of A1+ participants altered
their diabetes medications, either as prescribed by the study protocol or without investigators’
authorization.
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Prevalence of A1+ Genotypes
The A1+ genotypes were highly prevalent among both white and black participants. Among
the 49 whites, the overall prevalence was 47%. The genotype distribution was 4 A1A1 (8%);
19 A1A2 (39%); and 26 A2A2 (53%). This prevalence was significantly higher than the 29%
prevalence previously reported in whites without diabetes (p=0.01) (26), and was not
significantly different from the reported prevalence of these genotypes in white substance
abusers (26).
Among the 44 blacks, the A1+ genotype prevalence was 55%. The distribution was 5 A1A1
(11%); 19 A1A2 (43%); and 20 A2A2 (45%) (These numbers sum to less than 100%, due to
rounding). Comparison data on the prevalence of the A1+ genotypes among blacks without
diabetes are not available. The DRD2 genotype distribution was in Hardy-Weinberg
equilibrium in both black (p = 0.88) and white (p = 0.84) participants.
Diet and Body Weight
Black A1+ participants were, on average, more than 11 kg heavier than A1- participants at
baseline (110.4 kg vs 99.2 kg, P = 0.05), and ate significantly more fat, saturated fat, and
cholesterol, and less carbohydrate, compared with A1- participants (Table II). Among whites,
baseline carbohydrate intake was higher among A1+ participants, but other baseline nutritional
and anthropometric differences were not significant.
Among blacks, the A1+ genotypes were identified in 0% (0/2) of participants with BMI <25.0,
40% (2/5) with BMI = 25.0-29.9, 29% (2/7) with BMI = 30.0-34.9, 63% (12/19) with BMI =
35.0-39.9, and 73% (8/11) with BMI >40.0. Among whites, A1+ genotypes were identified in
50% (2/4) of participants with BMI <25.0, 62% (8/13) with BMI = 25.0-29.9, 31% (4/13) with
BMI = 30.0-34.9, 38% (5/13) with BMI = 35.0-39.9, and 67% (4/6) with BMI >40.0. The trend
of higher A1 prevalence among higher BMI categories did not reach statistical significance.
A series of linear regressions assessed the association of the A1+ genotypes with weight and
BMI, while controlling for age and for sex. In the initial models, age, but not sex, was associated
with weight and BMI. When the A1+ genotype was added to the models, age continued to be
associated with weight and BMI, but there was no association for genotype.
Exploratory Analyses of Clinical and Dietary Changes
Exploratory analyses examined clinical and dietary changes that occurred during the course of
the dietary intervention. For the vegan group, the reduction in A1c was significantly greater
among A1-, compared to A1+, white participants (-0.89 vs. -0.02, P=0.01). Other
anthropometric and glycemic changes were also generally greater among A1- participants,
compared with A1+ participants, for both blacks and whites assigned to the vegan diet (Table
III), but subgroup samples were small and most differences did not reach statistical
significance. In the ADA diet group, there were no significant differences in anthropometric
or clinical variables between A1- and A1+ participants. Using the regression models, neither
diet group nor DRD2 genotype status was a significant predictor of A1c change in either blacks
or whites.
Changes in energy and fat intake are depicted in Table IV. In the regression model for nutrient
intake changes, diet group was associated with changes in fat, saturated fat, cholesterol, protein,
carbohydrates, and fiber (all p <0.01 or lower). There was an interaction of race and the A1+
genotype as a predictor of change in fat intake (P=0.02): Blacks with A1+ genotypes reduced
fat intake more than did those with the A1- genotype; whites with A1+ genotypes reduced fat
intake less than did those with the A1- genotype.
Barnard et al. Page 5













Comparisons of the 2 Diets within Genotype Groups
The differences between the clinical effects of the vegan and ADA diets were strongly apparent
among the individuals with the A1- genotype of both races, but were greatly blunted among
those with the A1+ genotypes (Table V).
For both races, among individuals with the A1- genotype, the vegan diet was associated with
a greater A1c reduction (from baseline to the final value), compared to the ADA diet. The
weight change among black A1- participants associated with the vegan diet was also much
greater than in the ADA group (-8.2 kg vs +0.6 kg, p=0.02).
In contrast, among A1+ individuals, the differences in A1c changes between the two diet groups
were not significant. In black A1+ participants and white A1- and A1+ participants, differences
in weight change between groups did not reach significance.
DISCUSSION
The A1 allele prevalence was strikingly high in this sample of individuals with type 2 diabetes,
being identified in approximately half of all participants. In whites, this prevalence was
significantly higher than has been reported among whites without diabetes and was similar to
that observed in substance-abusing populations (26). The A1 allele prevalence was high in
black participants, as well, although comparison data for blacks without diabetes are not
available.
Body weight and intake of fat, saturated fat, and cholesterol were higher among blacks with
the A1 allele, compared with A1- participants. This dietary pattern difference was not evident
among whites, although A1+ whites ate more carbohydrate, compared with A1- whites, and
the A1+ individuals assigned to the vegan group were less successful in reducing fat intake
and A1c, compared with A1- individuals.
These findings raise the question as to whether diabetes, or the eating habits and elevated body
weight that contribute to it for some individuals, are in part the result of genetic contributors
that have commonalities with addictive disorders.
The Taq1A polymorphism is located ≈10 kb downstream of the DRD2 gene (1). The A1 allele
has been shown to be associated with low D2 dopamine receptor density in positron emission
tomography studies (10) and with a significantly lower mean relative glucose metabolic rate
in dopaminergic regions in the human brain (27). The allele has been associated with habitual
use of alcohol (2,3), cocaine (4), nicotine (5-7), and opioids (9), although some studies have
not supported these findings (8,28,29).
Kidd studied a four-site haplotype system, including three Taq1 restriction site polymorphisms
(Taq1A, B, and D) and one dinucleotide short tandem repeat polymorphism, in 28 distinct
populations, demonstrating the highest average heterozygosity in Africa, with lower average
heterozygosity in Europe, East Asia, and the Americas (30). This pattern suggests that homo
sapiens carried the haplotypes out of Africa, with successively less variation as they branched
out to the east and eventually to the Americas.
The role of dopamine in the brain’s reward and pleasure systems and in addictive behavior—
including dietary behavior—has been the subject of extensive research. Dopamine is involved
in appetite regulation, and genes regulating its availability influence eating behavior. (31,32)
However, the relationship between the DRD2 receptor and body weight is not simple or direct.
Evidence suggests that the A1 allele may be associated with an exaggerated reinforcing effect
of food or other psychological traits that, in turn, lead to pathological eating behavior. (33,
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34) Some have hypothesized that a dopaminergic deficit may lead to overeating as a form of
stimulus-seeking behavior (14). In turn, overeating may lead to weight gain and higher risk of
diabetes.
Some forms of disordered eating behavior, particularly compulsive eating, have been likened
to substance abuse, and there is a substantial comorbidity between these conditions (35).
Indeed, some evidence suggests that some foods (sugar, cheese, and meat—which were
proscribed on the low-fat, low-glycemic-index, vegan diet) have qualities akin to addictive
substances among some individuals (36,37).
If persistent food habits that lead to diabetes have similarities to substance abuse for some
individuals, dietary treatments may be more effective to the extent they use approaches that
have been helpful for substance abuse. These might include group support, family involvement,
and dietary interventions based on elimination of problem foods, rather than attempts to
moderate their intake. These considerations suggest that a vegan diet should be more effective
than the ADA diet. However, it was only in the A1- individuals where the two diets diverged
significantly in their effects on glycemic control.
If individuals with the A1 allele are prone to overeating, this may suggest that a caloric
restriction may be helpful in limiting this behavior. However, our results provide no clear
support for such an intervention. Among A1+ participants, weight loss was not significantly
greater in the ADA group, which included an energy restriction for overweight individuals,
compared with the vegan group, which did not. It remains an open question whether individuals
with disordered eating behavior are better able to conform to a quantitative restriction on food
intake, such as the calorie limit used in the ADA group, or to qualitative restrictions, such as
the exclusion of certain types of food as was required by the vegan diet.
Although the strikingly high prevalence of the A1+ genotypes in our study population supports
the possibility that variations in dopaminergic activity may influence the likelihood that
diabetes will manifest in genetically predisposed individuals, this finding does not settle the
question as to whether this relationship is mediated by dietary differences. Factors other than
diet may contribute to the apparent relationship between dopaminergic activity and diabetes.
Dopamine plays a key role in the central regulation of insulin action; bromocriptine, a D2
dopamine receptor agonist, significantly reduces A1c in individuals with type 2 diabetes (38).
Despite abundant prior research on associations between the A1 allele and substance abuse
and eating disorders, this is, to our knowledge, the first report of A1 allele prevalence in
individuals with diabetes. However, the present study has several limitations. Because the
overall study was designed to assess the effect of therapeutic diets on glycemic control, genetic
factors were not considered in either the determinations of sample size or the randomization
process. While this was less of a problem for baseline determinations, sample size was small
for specific racial and genetic groups after randomization to diet assignments. Because
randomization was done before genotyping, the two diet groups did not have equal distributions
of the represented genotypes. Dietary intake was determined based on 3-day dietary records,
which rely on self report. Finally, while we asked participants to avoid medication changes,
many participants altered their diabetes medications due to hypoglycemia or other reasons.
This is an inherent problem in diabetes research, and, in the present study, necessitated analyses
accounting for medication changes.
CONCLUSION
The A1 allele of the Taq1A polymorphism appears to be highly prevalent in individuals with
type 2 diabetes, similar to its prevalence in substance-abusing populations. The possibility that
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this allele may influence eating habits, body weight, or response to dietary treatment for
diabetes merits further investigation in larger populations.
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Not married 12 12
Married 8 12
Education 0.13
High school, partial or graduate 0 4
College, partial or graduate 13 12
Graduate degree 7 8
Occupation 0.28
Service occupation 4 2
Technical, sales, administrative 5 10









Not married 11 9
Married 15 14
Education 0.29
High school, partial or graduate 3 2
College, partial or graduate 15 9
Graduate degree 8 12
Occupation 0.38
Service occupation 3 1
Technical, sales, administrative 11 6
Professional or managerial 7 9
Retired 5 7
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Dietary Intake (per day) Energy (kilocalories) 1644 (100) 1909 (115) 0.10
Fat (% energy) 34.7 (1.5) 41.7 (1.5) 0.002
Saturated fat (% energy) 10.5 (0.6) 12.7 (0.6) 0.01
Carbohydrate (% energy) 47.6 (1.7) 41.4 (1.8) 0.02
Protein (% energy) 18.5 (1.3) 17.0 (0.6) 0.30
Sugar (% energy) 18.4 (1.2) 16.1 (1.2) 0.20
Fiber (g/1000 kcal) 11.0 (1.0) 9.5 (0.8) 0.24
Cholesterol (mg/1000 kcal) 144 (13) 197 (16) 0.02
Weight (kg) 99.2 (4.8) 110.4 (3.1) 0.05
BMI (kg/m2) 36.1 (2.0) 38.7 (1.2) 0.28
Waist circumference (cm) 111.3 (3.7) 118.2 (2.5) 0.12
Hip circumference (cm) 120.6 (3.6) 128.3 (2.4) 0.07
A1c (%) 8.15 (0.3) 7.86 (0.2) 0.36
White Participants
N 26 23
Dietary Intake (per day) Energy (kilocalories) 1793 (97) 1871 (131) 0.63
Fat (% energy) 36.3 (1.4) 32.8 (1.5) 0.09
Saturated fat (% energy) 12.0 (0.7) 11.0 (0.7) 0.31
Carbohydrate (% energy) 44.7 (2.0) 50.7 (1.6) 0.03
Protein (% energy) 20.0 (1.0) 17.9 (0.6) 0.09
Sugar (% energy) 17.3 (1.3) 17.8 (1.5) 0.82
Fiber (g/1000 kcal) 11.6 (0.9) 11.0 (1.0) 0.63
Cholesterol (mg/1000 kcal) 179 (16.7) 151 (22.9) 0.32
Weight (kg) 94.8 (4.4) 92.2 (5.0) 0.70
BMI (kg/m2) 33.3 (1.3) 32.5 (1.5) 0.70
Waist circumference (cm) 110.3 (3.7) 107.5 (3.6) 0.59
Hip circumference (cm) 117.5 (3.0) 114.8 (3.3) 0.55
A1c (%) 8.03 (0.20) 8.02 (0.25) 0.97
*
Mean values. Standard error of the mean is indicated in parenthesis
†
P-values for between-group (A1- vs A1+) differences.
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